Gabriel Noah Mannis, MD

Offices

1 location · Stanford Health Care · 3,152 clinicians in this group

Looking this up.

Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.

Plans that list them

17 plans · 3 carriers

A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Mannis’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.

17 of 17 plans

Sort by

Plans whose provider directory lists this clinician

Alignment Health BreathEasy (HMO C-SNP)	Alignment Health Plan	Listed	Oct 3, 2026
Alignment Health Clarity (HMO C-SNP)	Alignment Health Plan	Listed	Oct 3, 2026
Alignment Health Harmony (HMO)	Alignment Health Plan	Listed	Oct 3, 2026
Alignment Health Heart & Diabetes (HMO C-SNP)	Alignment Health Plan	Listed	Oct 3, 2026
Alignment Health Heart & Diabetes CalPlus (HMO C-SNP)	Alignment Health Plan	Listed	Oct 3, 2026
Alignment Health Heart & Diabetes Care (HMO C-SNP)	Alignment Health Plan	Listed	Sep 28, 2026
Alignment Health Heart & Diabetes Choice (HMO C-SNP)	Alignment Health Plan	Listed	Sep 28, 2026
Alignment Health Honor+ Plan (HMO)	Alignment Health Plan	Listed	Oct 3, 2026
Alignment Health My Choice CalCare (HMO)	Alignment Health Plan	Listed	Oct 3, 2026
Alignment Health Silicon (HMO C-SNP)	Alignment Health Plan	Listed	Oct 3, 2026
Alignment Health smartHMO (HMO)	Alignment Health Plan	Listed	Oct 3, 2026
Alignment Health the ONE (HMO)	Alignment Health Plan	Listed	Oct 3, 2026
SCAN Balance (HMO C-SNP)	SCAN Health Plan	Listed	Oct 3, 2026
SCAN Classic (HMO)	SCAN Health Plan	Listed	Oct 3, 2026
SCAN MyChoice (HMO)	SCAN Health Plan	Listed	Oct 3, 2026
SCAN Strive (HMO C-SNP)	SCAN Health Plan	Listed	Oct 3, 2026
DualConnect (HMO D-SNP)	Santa Clara Family Health Plan	Listed	Sep 1, 2026

California Medical Board record

Licence A110736 · Current

Licensed to practise in California · since 2010 · expires 2028-01-31 · University of California, Davis School of Medicine.

No disciplinary actions, convictions, malpractice judgments or citations in this record.

Hospitals they work in

1 hospital

These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.

Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend it
Overall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024

See every measure and the patient survey for Stanford Health Care

Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Sort by

Every scored measure at Stanford Health Care

Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths	5.31 (4.24 to 6.37) · 8,661 cases	Worse	Jul 2022 – Jun 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits	14.1 (12.7 to 15.7) · 2,191 cases	Worse	Jan 2024 – Dec 2024
Postoperative respiratory failure rateComplications and deaths	4.08 (1.95 to 6.21) · 5,296 cases	Better	Jul 2022 – Jun 2024
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections	0.317	Better	Oct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections	0.446	Better	Oct 2024 – Sep 2025
SSI - Colon SurgeryInfections	0.241	Better	Oct 2024 – Sep 2025
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits	0.7 (0.6 to 0.9) · 3,348 cases	Better	Jan 2024 – Dec 2024
Abdominopelvic accidental puncture or laceration rateComplications and deaths	1.06 (0.45 to 1.67) · 5,374 cases	No different	Jul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths	0.86 (0.72 to 1)	No different	Jul 2022 – Jun 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths	166.09 (137.88 to 194.3) · 470 cases	No different	Jul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths	1.1 · 192 cases	None	Jul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths	6.4 · 146 cases	None	Jul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths	9.7 · 253 cases	None	Jul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths	6.3 · 880 cases	None	Jul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths	10.3 · 935 cases	None	Jul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths	8.7 · 501 cases	None	Jul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths	2.1 · 7,730 cases	None	Jul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths	0.13 (0 to 0.27) · 20,799 cases	No different	Jul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths	0.28 (0.14 to 0.43) · 23,182 cases	No different	Jul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths	0.94 (0.2 to 1.68) · 5,694 cases	No different	Jul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths	2.36 (1.54 to 3.19) · 7,846 cases	No different	Jul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths	5.2 (3.76 to 6.64) · 5,603 cases	No different	Jul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths	1.38 (0.23 to 2.53) · 2,211 cases	No different	Jul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths	0.52 (0.21 to 0.83) · 19,915 cases	No different	Jul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths	3.6 · 416 cases	None	Apr 2023 – Mar 2025
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections	0.869	No different	Oct 2024 – Sep 2025
MRSA BacteremiaInfections	0.857	No different	Oct 2024 – Sep 2025
SSI - Abdominal HysterectomyInfections	0.368	No different	Oct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits	16.2 · 247 cases	None	Jul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits	20.5 · 1,021 cases	None	Jul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits	47.8 · 258 cases	None	Jul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits	-1.6 · 990 cases	None	Jul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits	20.8 · 976 cases	None	Jul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits	16.5 · 959 cases	None	Jul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits	5.2 (4.4 to 6.2) · 2,191 cases	No different	Jan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits	5.1 · 425 cases	None	Jul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits	9.6 · 158 cases	None	Jul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits	19.6 · 183 cases	None	Jul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits	12.7 (10.4 to 15.4) · 4,578 cases	No different	Jan 2022 – Dec 2024

What patients said (6,810 patients answered, 25% of those asked)

Sort by

Patient survey stars by topic at Stanford Health Care

Cleanliness	4
Nurse communication	4
Doctor communication	4
Communication about medicines	3
Discharge information	4
Overall hospital rating	4
Quietness	2
Recommend hospital	5

Sort by

Share of patients giving the best answer at Stanford Health Care

Room was "always" clean	75%
Nurses "always" communicated well	82%
Doctors "always" communicated well	81%
Staff "always" explained	63%
Yes, staff "did" give patients this information	89%
Yes, staff "did" give patients information about help after discharge	89%
Doctors "always" explained things so they could understand	76%
Doctors "always" listened carefully	80%
Doctors "always" treated them with courtesy and respect	87%
Patients who gave a rating of "9" or "10" (high)	79%
Staff "always" explained new medications	76%
Nurses "always" explained things so they could understand	77%
Nurses "always" listened carefully	79%
Nurses "always" treated them with courtesy and respect	88%
"Always" quiet at night	53%
"YES", patients would definitely recommend the hospital	83%
Staff "always" explained possible side effects	50%
Yes, staff "did" give patients information about possible symptoms	90%

Original Medicare doctor bills

$84,072

Medicare paid this office $84,072 for 132 people.

This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.

Sort by

Largest Original Medicare bills

Long return visit (40+ min)	35	$20,201	$128
Return visit (30+ min)	56	$18,012	$116
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes	44	$17,228	$106
Long return visit (40+ min)	35	$12,004	$156
Return visit (30+ min)	26	$5,008	$82

See all 9 services

Sort by

Every Original Medicare service billed

Long return visit (40+ min)	35	$20,201	$128
Return visit (30+ min)	56	$18,012	$116
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes	44	$17,228	$106
Long return visit (40+ min)	35	$12,004	$156
Return visit (30+ min)	26	$5,008	$82
Initial hospital care with moderate level of medical decision making at least 75 minutes	28	$4,295	$143
New patient visit (60+ min)	14	$2,756	$197
New patient visit (60+ min)	16	$2,444	$153
Hospital discharge day management, more than 30 minutes	22	$2,125	$97

Who their Medicare patients are

132 Original Medicare patients in 2024. Average age 76 · Women 39% · Also on Medicaid 20% · Health risk score 3.34. Sicker patients than 9 in 10 peers; the typical hematology-oncology clinician is at 2.04.

Conditions among them: High blood pressure 75% · Chronic kidney disease 44% · Atrial fibrillation 35% · Diabetes 27% · Coronary heart disease 27% · Heart failure 27% · Depression 20% · Cancer 18% · Dementia 17% · COPD 16% · Stroke 14%.

The office billed $344,445, Medicare allowed $109,537 and paid $84,072; for 696 services of 6 kinds.

Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.

Year by year

Sort by

Original Medicare by year

2024	132	696	76	3.34	$344,445	$84,072
2023	137	839	74	3.13	$375,595	$91,462
2022	133	815	73	3.58	$359,379	$87,296
2021	119	810	74	3.37	$361,796	$88,370
2020	112	764	73	3.93	$313,390	$73,073
2019	114	476	72	2.64	$175,858	$48,249
2018	125	356	70	3.33	$309,330	$31,335
2017	113	366	69	3.35	$331,498	$31,790
2016	134	606	67	3.28	$627,090	$49,720
2015	105	414	67	2.23	$414,547	$34,746
2014	17	22	70	2.36	$15,231	$2,195

Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.

See the services billed each year

2023: 6 services

Sort by

Original Medicare services billed in 2023

Subsequent hospital care with moderate levelof medical decision making at least 50 minutes	57	$31,366	$107
Long return visit (40+ min)	62	$29,323	$127
Return visit (30+ min)	69	$16,159	$87
Initial hospital care with moderate level of medical decision making at least 75 minutes	33	$5,649	$153
Hospital discharge day management, more than 30 minutes	30	$3,931	$103
New patient visit (60+ min)	23	$3,371	$147

2022: 6 services

Sort by

Original Medicare services billed in 2022

Long return visit (40+ min)	58	$36,440	$125
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes	59	$27,957	$88
Return visit (30+ min)	36	$7,560	$82
Initial hospital care with moderate level of medical decision making at least 75 minutes	36	$6,544	$168
Hospital discharge day management, more than 30 minutes	36	$3,760	$94
New patient visit (60+ min)	20	$3,367	$168

2021: 6 services

Sort by

Original Medicare services billed in 2021

Long return visit (40+ min)	56	$30,330	$128
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes	56	$27,442	$92
Return visit (30+ min)	43	$11,919	$83
Initial hospital care with moderate level of medical decision making at least 75 minutes	36	$8,789	$183
Hospital discharge day management, more than 30 minutes	43	$5,292	$98
New patient visit (60+ min)	22	$3,699	$168

2020: 8 services

Sort by

Original Medicare services billed in 2020

Subsequent hospital care with moderate levelof medical decision making at least 50 minutes	53	$26,415	$95
Long return visit (40+ min)	42	$15,725	$96
Return visit (30+ min)	34	$10,014	$72
Initial hospital care with moderate level of medical decision making at least 75 minutes	43	$8,560	$178
Hospital discharge day management, more than 30 minutes	38	$4,770	$101
Return visit (30+ min)	16	$2,316	$77
New patient visit (60+ min)	13	$1,991	$153
Long return visit (40+ min)	12	$1,451	$97

2019: 6 services

Sort by

Original Medicare services billed in 2019

Subsequent hospital care with moderate levelof medical decision making at least 50 minutes	42	$17,494	$94
Long return visit (40+ min)	54	$15,856	$98
Initial hospital care with moderate level of medical decision making at least 75 minutes	24	$4,591	$184
New patient visit (60+ min)	18	$2,743	$152
Hospital discharge day management, more than 30 minutes	23	$2,580	$99
Return visit (30+ min)	13	$1,506	$72

2018: 4 services

Sort by

Original Medicare services billed in 2018

Long return visit (40+ min)	54	$10,060	$97
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes	28	$8,245	$93
Return visit (30+ min)	51	$6,359	$66
New patient visit (60+ min)	14	$1,799	$128

2017: 5 services

Sort by

Original Medicare services billed in 2017

Long return visit (40+ min)	39	$8,773	$95
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes	22	$8,594	$90
Return visit (30+ min)	44	$6,417	$64
New patient visit (60+ min)	13	$1,861	$143
Biopsy of bone marrow	12	$721	$60

2016: 5 services

Sort by

Original Medicare services billed in 2016

Subsequent hospital care with moderate levelof medical decision making at least 50 minutes	34	$13,742	$92
Long return visit (40+ min)	41	$13,294	$94
Return visit (30+ min)	60	$11,068	$67
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes	18	$2,369	$64
Biopsy of bone marrow	30	$2,299	$68

2015: 7 services

Sort by

Original Medicare services billed in 2015

Long return visit (40+ min)	35	$10,499	$93
Return visit (30+ min)	29	$6,538	$65
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes	19	$6,449	$92
New patient visit (60+ min)	13	$1,847	$142
New patient visit (45+ min)	14	$1,533	$109
Biopsy of bone marrow	15	$1,264	$67
Short return visit (20+ min)	15	$947	$41

Medicaid work

$1,970 in 2024

Medicaid paid $1,970 for 28 billed services this clinician did in 2024, up to 13 people in a month for one service.

Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.

Sort by

Largest Medicaid services in 2024

Return visit (30+ min)	28	$1,970

Sort by

Medicaid work by year

2024	28	1	13	$1,970
2023	56	2	14	$1,810
2022	41	1	12	$2,507
2019	76	2	15	$3,705
2018	980	6	28	$24,551

See the largest Medicaid services in earlier years

2023

Sort by

Largest Medicaid services in 2023

SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES	41	$1,100
Return visit (30+ min)	15	$709

2022

Sort by

Largest Medicaid services in 2022

SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES	41	$2,507

2019

Sort by

Largest Medicaid services in 2019

SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES	61	$2,835
Long return visit (40+ min)	15	$870

2018

Sort by

Largest Medicaid services in 2018

Long return visit (40+ min)	261	$16,194
COMPREHENSIVE METABOLIC PANEL	284	$2,956
Return visit (30+ min)	42	$2,535
Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count	312	$2,479
Measurement of magnesium	34	$254
Lactate dehydrogenase (LD), (LDH)	47	$133

Drugs they prescribed that Part D paid

$1,998,547

Pharmacies billed $1,998,547 in 2024.

This is pharmacy cost, not the office bill, and not what patients paid.

143 generic and 144 brand-name prescriptions · $1,998,547 in drug cost · 14 antibiotic prescriptions.

Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.

Sort by

Largest Part D drug costs

Tibsovo	18	$588,185	$32,677
Venclexta	57	$380,178	$6,670
Vanflyta	11	$297,071	$27,006
Inqovi	18	$137,451	$7,636
Cresemba	11	$67,196	$6,109

See all 6 drugs

Sort by

Every Part D drug this clinician prescribed

Tibsovo	18	$588,185	$32,677
Venclexta	57	$380,178	$6,670
Vanflyta	11	$297,071	$27,006
Inqovi	18	$137,451	$7,636
Cresemba	11	$67,196	$6,109
Allopurinol	11	$37	$3

Year by year

Sort by

Part D prescribing by year

2024	287	64	None	50%	$1,998,547
2023	215	50	None	53%	$1,010,762
2022	267	63	None	49%	$1,585,633
2021	212	48	None	48%	$1,039,907
2020	210	48	None	None	$879,738
2019	235	52	None	28%	$655,024
2018	594	78	None	27%	$1,354,145
2017	394	75	4% (15)	26%	$1,172,640
2016	505	76	4% (20)	None	$1,076,998
2015	235	47	7% (17)	23%	$403,468
2014	11	None	None	None	$10,040
2013	16	None	None	None	$26,019

Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.

See the drugs prescribed each year

2023: 2 drugs

Sort by

Part D drugs prescribed in 2023

Venclexta	54	$265,103	$4,909
Levofloxacin	19	$583	$31

2022: 6 drugs

Sort by

Part D drugs prescribed in 2022

Idhifa	19	$593,062	$31,214
Venclexta	40	$257,312	$6,433
Levofloxacin	20	$386	$19
Ondansetron	11	$208	$19
Acyclovir	13	$127	$10
Allopurinol	11	$108	$10

2021: 6 drugs

Sort by

Part D drugs prescribed in 2021

Venclexta	48	$256,494	$5,344
Inqovi	12	$88,722	$7,393
Posaconazole	15	$45,038	$3,003
Levofloxacin	22	$645	$29
Ondansetron	11	$269	$24
Allopurinol	11	$89	$8

2020: 4 drugs

Sort by

Part D drugs prescribed in 2020

Venclexta	32	$204,556	$6,392
Levofloxacin	15	$661	$44
Acyclovir	18	$308	$17
Allopurinol	13	$119	$9

2019: 4 drugs

Sort by

Part D drugs prescribed in 2019

Venclexta	22	$199,665	$9,076
Acyclovir	34	$525	$15
Allopurinol	35	$313	$9
Ondansetron	15	$306	$20

2018: 20 drugs

Sort by

Part D drugs prescribed in 2018

Revlimid	27	$471,764	$17,473
Pomalyst	12	$144,664	$12,055
Venclexta	23	$133,479	$5,803
Jakafi	14	$117,896	$8,421
Noxafil	17	$93,977	$5,528
Voriconazole	19	$18,508	$974
Xarelto	11	$9,435	$858
Ursodiol	11	$3,882	$353
Levofloxacin	26	$1,417	$55
Dapsone	19	$1,125	$59
Potassium Chloride	26	$1,025	$39
Acyclovir	62	$887	$14
Ondansetron	26	$619	$24
Hydroxyurea	21	$609	$29
Gabapentin	16	$488	$31
Sulfamethoxazole-Trimethoprim	27	$309	$11
Atorvastatin	11	$136	$12
Prednisone	16	$129	$8
Metformin	11	$88	$8
Dexamethasone	13	$65	$5

2017: 9 drugs

Sort by

Part D drugs prescribed in 2017

Revlimid	46	$700,264	$15,223
Pomalyst	18	$250,589	$13,922
Acyclovir	49	$790	$16
Valacyclovir	19	$754	$40
Labetalol	11	$654	$59
Potassium Chloride	12	$361	$30
Sulfamethoxazole-Trimethoprim	18	$134	$7
Pantoprazole	11	$80	$7
Ondansetron	11	$63	$6

2016: 14 drugs

Sort by

Part D drugs prescribed in 2016

Revlimid	49	$616,105	$12,574
Jakafi	11	$119,129	$10,830
Voriconazole	16	$9,399	$587
Xarelto	15	$5,404	$360
Ursodiol	18	$4,146	$230
Acyclovir	89	$1,621	$18
Levofloxacin	14	$842	$60
Labetalol	12	$649	$54
Potassium Chloride	13	$298	$23
Zolpidem	15	$248	$17
Gabapentin	13	$189	$15
Sulfamethoxazole-Trimethoprim	24	$161	$7
Dexamethasone	19	$113	$6
Amlodipine Besylate	11	$38	$3

2015: 4 drugs

Sort by

Part D drugs prescribed in 2015

Revlimid	27	$298,203	$11,045
Acyclovir	29	$387	$13
Levofloxacin	13	$244	$19
Sulfamethoxazole-Trimethoprim	21	$80	$4

Money from drug and device companies

$29,416 in 2025

Sort by

Industry payments by year

2025	11	27	$28,562	$29,416
2024	6	36	$24,325	$28,969
2023	7	19	$16,260	$17,226
2022	7	20	$24,781	$26,171
2021	6	17	$20,992	$21,477
2020	6	20	$31,696	$32,687
2019	7	27	$10,760	$15,240

Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.

A payment is not proof that care is biased.

Sort by

Payments by company

Abbvie	Venclexta	$9,290	10 payments Consulting · 2025-12-19 · $2,100 Meals · 2025-12-04 · $22 Meals · 2025-12-04 · $135 Consulting · 2025-05-28 · $700 Meals for Venclexta · 2025-04-03 · $12 Consulting for Venclexta · 2025-03-06 · $700 Consulting for Venclexta · 2025-02-20 · $1,750 Meals for Venclexta · 2025-02-09 · $46 Consulting for Venclexta · 2025-01-17 · $1,725 Consulting · 2025-01-02 · $2,100
Taiho Oncology	Inqovi	$3,900	1 payment Consulting for Inqovi · 2025-02-19 · $3,900
Astellas Pharma Global Development	Xospata	$3,718	2 payments Consulting for Xospata · 2025-04-30 · $2,704 Consulting for Xospata · 2025-03-21 · $1,014
Daiichi Sankyo	Vanflyta	$3,393	4 payments Consulting for Vanflyta · 2025-12-23 · $3,225 Meals for Datroway · 2025-12-04 · $91 Meals for Datroway · 2025-12-04 · $52 Meals for Datroway · 2025-12-04 · $25
Janssen Scientific Affairs	None	$2,659	3 payments Consulting · 2025-09-23 · $2,503 Meals · 2025-09-23 · $14 Meals · 2025-09-20 · $142
Stemline Therapeutics	Elzonris	$2,340	1 payment Consulting for Elzonris · 2025-04-18 · $2,340

See all 27 published payments

Sort by

Every published payment

Daiichi Sankyo	Consulting · 2025-12-23	Vanflyta	$3,225
Syndax Pharmaceuticals	Consulting · 2025-12-22	Revuforj	$800
Abbvie	Consulting · 2025-12-19	None	$2,100
Genentech USA	Consulting · 2025-12-06	Venclexta	$1,640
Genentech USA	Meals · 2025-12-06	Venclexta	$207
Daiichi Sankyo	Meals · 2025-12-04	Datroway	$91
Daiichi Sankyo	Meals · 2025-12-04	Datroway	$52
Daiichi Sankyo	Meals · 2025-12-04	Datroway	$25
Abbvie	Meals · 2025-12-04	None	$22
Abbvie	Meals · 2025-12-04	None	$135
Astellas Pharma US	Consulting · 2025-10-17	Xospata	$676
Janssen Scientific Affairs	Consulting · 2025-09-23	None	$2,503
Janssen Scientific Affairs	Meals · 2025-09-23	None	$14
Janssen Scientific Affairs	Meals · 2025-09-20	None	$142
Rigel Pharmaceuticals	Honoraria · 2025-09-05	Rezlidhia	$685
Celgene	Meals · 2025-07-09	Reblozyl	$107
Abbvie	Consulting · 2025-05-28	None	$700
Astellas Pharma Global Development	Consulting · 2025-04-30	Xospata	$2,704
Stemline Therapeutics	Consulting · 2025-04-18	Elzonris	$2,340
Abbvie	Meals · 2025-04-03	Venclexta	$12
Astellas Pharma Global Development	Consulting · 2025-03-21	Xospata	$1,014
Abbvie	Consulting · 2025-03-06	Venclexta	$700
Abbvie	Consulting · 2025-02-20	Venclexta	$1,750
Taiho Oncology	Consulting · 2025-02-19	Inqovi	$3,900
Abbvie	Meals · 2025-02-09	Venclexta	$46
Abbvie	Consulting · 2025-01-17	Venclexta	$1,725
Abbvie	Consulting · 2025-01-02	None	$2,100

See earlier years (2024, 2023, 2022, 2021, 2020, 2019)

2024: $28,969

Sort by

Payments by company in 2024

Daiichi Sankyo	Vanflyta	$8,800	10 payments Consulting for Vanflyta · 2024-06-12 · $3,548 Consulting for Vanflyta · 2024-05-15 · $3,548 Travel for Vanflyta · 2024-04-20 · $183 Meals for Vanflyta · 2024-04-19 · $132 Meals for Vanflyta · 2024-04-19 · $61 Meals for Vanflyta · 2024-04-19 · $40 Travel for Vanflyta · 2024-04-18 · $595 Travel for Vanflyta · 2024-04-18 · $253 Travel for Vanflyta · 2024-04-18 · $337 Meals for Vanflyta · 2024-04-18 · $104
Stemline Therapeutics	Elzonris	$8,530	7 payments Meals for Elzonris · 2024-12-09 · $17 Consulting for Elzonris · 2024-08-06 · $3,120 Consulting for Elzonris · 2024-06-14 · $2,220 Meals for Elzonris · 2024-06-14 · $31 Travel for Elzonris · 2024-01-31 · $493 Consulting for Elzonris · 2024-01-31 · $2,590 Meals for Elzonris · 2024-01-30 · $59
Abbvie	Venclexta	$6,898	12 payments Meals for Venclexta · 2024-12-07 · $150 Meals · 2024-12-05 · $30 Meals · 2024-12-05 · $148 Consulting for Venclexta · 2024-03-29 · $5,750 Meals for Epkinly · 2024-02-01 · $38 Meals for Venclexta · 2024-02-01 · $7 Travel for Venclexta · 2024-02-01 · $81 Travel for Venclexta · 2024-02-01 · $161 Meals for Venclexta · 2024-01-31 · $126 Travel for Venclexta · 2024-01-31 · $247 Travel for Venclexta · 2024-01-31 · $104 Meals for Venclexta · 2024-01-11 · $56
Servier Pharmaceuticals	Tibsovo	$3,724	5 payments Consulting for Tibsovo · 2024-11-15 · $2,800 Travel for Tibsovo · 2024-11-15 · $369 Travel for Tibsovo · 2024-11-15 · $136 Travel for Tibsovo · 2024-11-15 · $383 Meals for Tibsovo · 2024-11-15 · $36
Aadi Bioscience	Fyarro	$750	1 payment Consulting for Fyarro · 2024-08-28 · $750
Taiho Oncology	Inqovi	$267	1 payment Meals for Inqovi · 2024-12-06 · $267

2023: $17,226

Sort by

Payments by company in 2023

Genentech	Venclexta	$8,093	3 payments Travel for Venclexta · 2023-05-20 · $60 Consulting for Venclexta · 2023-05-20 · $7,790 Meals for Venclexta · 2023-05-20 · $243
Abbvie	Venclexta	$3,044	6 payments Consulting for Venclexta · 2023-12-21 · $1,150 Meals for Venclexta · 2023-12-09 · $131 Consulting for Venclexta · 2023-07-21 · $288 Consulting for Venclexta · 2023-05-02 · $1,438 Meals for Venclexta · 2023-04-19 · $10 Meals for Venclexta · 2023-04-18 · $28
ImmunoGen	None	$2,940	2 payments Meals · 2023-12-07 · $140 Consulting · 2023-12-07 · $2,800
Rigel Pharmaceuticals	Rezlidhia	$2,140	2 payments Honoraria for Rezlidhia · 2023-12-22 · $2,055 Meals for Rezlidhia · 2023-12-08 · $85
Stemline Therapeutics	Elzonris	$828	3 payments Meals for Orserdu · 2023-12-10 · $72 Consulting for Elzonris · 2023-12-10 · $740 Meals for Elzonris · 2023-05-04 · $16
Celgene	Reblozyl	$169	2 payments Meals for Reblozyl · 2023-09-27 · $106 Meals for Reblozyl · 2023-06-03 · $63
Daiichi Sankyo	None	$13	1 payment Meals · 2023-10-23 · $13

2022: $26,171

Sort by

Payments by company in 2022

Servier Pharmaceuticals	Tibsovo	$6,873	5 payments Travel for Tibsovo · 2022-07-21 · $165 Meals for Tibsovo · 2022-07-21 · $38 Consulting for Tibsovo · 2022-07-17 · $5,780 Travel for Tibsovo · 2022-06-15 · $432 Travel for Tibsovo · 2022-05-31 · $457
Astellas Pharma Global Development	Xospata	$6,200	2 payments Consulting for Xospata · 2022-12-05 · $3,100 Consulting for Xospata · 2022-05-04 · $3,100
Abbvie	Venclexta	$5,308	7 payments Consulting for Venclexta · 2022-12-15 · $1,438 Meals for Venclexta · 2022-12-10 · $109 Consulting for Venclexta · 2022-11-10 · $575 Meals for Venclexta · 2022-10-11 · $14 Meals for Venclexta · 2022-07-07 · $10 Consulting for Venclexta · 2022-06-17 · $1,438 Consulting for Venclexta · 2022-02-18 · $1,725
Stemline Therapeutics	Elzonris	$3,900	1 payment Paid to speak or teach for Elzonris · 2022-01-13 · $3,900
Celgene	Onureg	$2,225	3 payments Meals for Onureg · 2022-12-11 · $24 Meals for Onureg · 2022-05-05 · $125 Consulting · 2022-01-27 · $2,076
Genentech USA	Venclexta	$1,650	1 payment Consulting for Venclexta · 2022-02-24 · $1,650
Jazz Pharmaceuticals	Vyxeos	$15	1 payment Meals for Vyxeos · 2022-08-29 · $15

2021: $21,477

Sort by

Payments by company in 2021

Astellas Pharma Global Development	Xospata	$9,300	3 payments Consulting for Xospata · 2021-04-14 · $3,100 Consulting for Xospata · 2021-03-31 · $3,100 Consulting for Xospata · 2021-02-12 · $3,100
AbbVie	Venclexta	$6,770	5 payments Meals for Venclexta · 2021-12-12 · $127 Meals for Venclexta · 2021-11-02 · $30 Consulting for Venclexta · 2021-08-04 · $288 Consulting for Venclexta · 2021-06-11 · $1,725 Consulting for Venclexta · 2021-05-19 · $4,600
Genentech USA	Venclexta	$3,381	4 payments Meals for Venclexta · 2021-12-12 · $77 Meals for Venclexta · 2021-10-26 · $5 Consulting for Venclexta · 2021-09-09 · $1,650 Consulting for Venclexta · 2021-03-12 · $1,650
Celgene	Onureg	$1,897	3 payments Meals for Onureg · 2021-12-12 · $18 Meals for Onureg · 2021-07-29 · $100 Paid to speak or teach for Onureg · 2021-04-13 · $1,779
Stemline Therapeutics	Elzonris	$102	1 payment Meals for Elzonris · 2021-07-23 · $102
Pharmacyclics LLC An AbbVie	Imbruvica	$27	1 payment Meals for Imbruvica · 2021-05-19 · $27

2020: $32,687

Sort by

Payments by company in 2020

Agios Pharmaceuticals	Tibsovo	$12,650	7 payments Consulting for Tibsovo · 2020-11-04 · $4,500 Travel for Tibsovo · 2020-03-04 · $78 Consulting for Tibsovo · 2020-02-28 · $5,273 Meals for Tibsovo · 2020-02-05 · $87 Travel for Tibsovo · 2020-02-04 · $348 Travel for Tibsovo · 2020-01-16 · $283 Consulting for Tibsovo · 2020-01-09 · $2,081
Genentech USA	Venclexta	$7,700	4 payments Consulting for Venclexta · 2020-10-29 · $1,650 Consulting for Venclexta · 2020-08-20 · $1,650 Consulting for Venclexta · 2020-04-18 · $2,750 Consulting for Venclexta · 2020-04-11 · $1,650
AbbVie	Venclexta	$4,600	4 payments Consulting for Venclexta · 2020-12-02 · $1,438 Consulting for Venclexta · 2020-07-20 · $575 Consulting for Venclexta · 2020-06-11 · $2,013 Consulting for Venclexta · 2020-01-15 · $575
Celgene	Reblozyl	$3,757	3 payments Consulting for Reblozyl · 2020-02-05 · $3,563 Meals for Reblozyl · 2020-01-25 · $128 Travel for Reblozyl · 2020-01-25 · $66
Stemline Therapeutics	Elzonris	$2,500	1 payment Honoraria for Elzonris · 2020-10-27 · $2,500
Pfizer International	Bosulif	$1,480	1 payment Paid to speak or teach for Bosulif · 2020-11-20 · $1,480

2019: $15,240

Sort by

Payments by company in 2019

Agios Pharmaceuticals	Tibsovo	$9,925	12 payments Honoraria for Tibsovo · 2019-12-08 · $2,220 Meals for Tibsovo · 2019-12-08 · $140 Meals for Tibsovo · 2019-12-05 · $140 Travel for Tibsovo · 2019-11-21 · $82 Consulting for Tibsovo · 2019-10-31 · $4,400 Travel for Tibsovo · 2019-10-18 · $354 Meals for Tibsovo · 2019-10-18 · $17 Meals for Tibsovo · 2019-10-18 · $27 Travel for Tibsovo · 2019-10-17 · $280 Travel for Tibsovo · 2019-10-17 · $602 Honoraria for Tibsovo · 2019-10-08 · $555 Honoraria for Tibsovo · 2019-08-15 · $1,110
Genentech	Non-Covered Product	$2,475	1 payment Consulting for Non-Covered Product · 2019-12-10 · $2,475
Jazz Pharmaceuticals	Vyxeos	$1,387	5 payments Meals for Vyxeos · 2019-11-01 · $115 Travel for Vyxeos · 2019-11-01 · $210 Travel for Vyxeos · 2019-11-01 · $432 Travel for Vyxeos · 2019-11-01 · $160 Travel for Defitelio · 2019-07-09 · $471
Astellas Pharma Global Development	Xospata	$1,268	4 payments Travel for Xospata · 2019-04-11 · $456 Travel for Xospata · 2019-01-17 · $356 Travel for Xospata · 2019-01-17 · $386 Travel for Xospata · 2019-01-17 · $70
Novartis Pharmaceuticals	Kymriah	$142	3 payments Meals for Kymriah · 2019-12-09 · $56 Meals · 2019-12-06 · $25 Meals for Kymriah · 2019-08-13 · $61
Daiichi Sankyo	None	$26	1 payment Meals · 2019-03-06 · $26
Stemline Therapeutics	Elzonris	$17	1 payment Education for Elzonris · 2019-09-13 · $17

Research money

Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.

Sort by

Research payments by company and study

Otsuka Pharmaceutical Co., Ltd. · A Single-Arm, Open-Label Pharmacokinetic, Safety, and Efficacy Study of Astx727 in Combination With Venetoclax in Adult Patients With Acute Myeloid Leukemia · 2022	Their institution	$420,729
JAZZ PHARMACEUTICALS INC. · V-Fast: A Phase 1b Master Trial To Investigatecpx-351 Combined With Various Targeted Agents in Subjects With Previously Untreated Acute Myeloid Leukemia · 2020	Their institution	$381,089
JAZZ PHARMACEUTICALS INC. · V-Fast: A Phase 1b Master Trial To Investigate Cpx-351 Combined With Various Targeted Agents in Subjects With Previously Untreated Acute Myeloid Leukemia · 2021	Their institution	$328,982
TAIHO ONCOLOGY, INC. · Astx727-07 · 2025	Their institution	$293,365
Otsuka Pharmaceutical Co., Ltd. · A Single-Arm, Open-Label Pharmacokinetic, Safety, and Efficacy Study of Astx727 in Combination With Venetoclax in Adult Patients With Acute Myeloid Leukemia · 2021	Their institution	$267,988
ABBVIE INC. · A Phase 2 Randomized Study Comparing Venetoclax and Hypomethylating Therapy To Induction Chemotherapy for Newly Diagnosed Fit Adults With Acute Myeloid Leukemia · 2024	Their institution	$261,893
Syndax Pharmaceuticals, Inc. · A Phase 1/2, Open-Label, Dose-Escalation and Dose-Expansion Cohort Study of Sndx-5613 in Patients With Relapsed/Refractory Leukemias, Including Those Harboring An Mll/Kmt2a Gene Rearrangement Or Nucleophosmin 1 (Npm1) Mutation · 2025	Their institution	$175,290
JAZZ PHARMACEUTICALS INC. · Jzp025-101, V-Fast: A Phase 1b Master Trial To Investigatecpx-351 Combined With Various Targeted Agents in Subjects With Previously Untreated Acute Myeloid Leukemia · 2020	Their institution	$164,440
Otsuka Pharmaceutical Co., Ltd. · A Single-Arm, Open-Label Pharmacokinetic, Safety, and Efficacy Study of Astx727 in Combination With Venetoclax in Adult Patients With Acute Myeloid Leukemia · 2023	Their institution	$125,791
Celgene Corporation · Ph Ib Monotherapy R/R Aml & R/R Mds - A Phase 1, Open-Label, Dose Finding Study of Cc-95251 Alone and in Combination With Antineoplastic Agents in Subjects With Acute Myeloid Leukemia and Myelodysplastic Syndromes · 2023	Their institution	$119,908
MACROGENICS, INC. · Flotetuzumab in Primary Induction Failure Pif Or Early Relapse Er Acute Myeloid Leukemia Aml · 2023	Their institution	$118,440
JAZZ PHARMACEUTICALS INC. · V-Fast: A Phase 1b Master Trial To Investigate Cpx351combined With Various Targeted Agents in Subjects With Previously Untreated Acute Myeloid Leukemia · 2020	Their institution	$94,020
Daiichi Sankyo Inc. · Vanflyta · 2025	Their institution	$82,658
JAZZ PHARMACEUTICALS INC. · V-Fast: A Phase 1b Master Trial To Investigate Cpx-351 Combined With Various Targeted Agents in Subjects With Previously Untreated Acute Myeloid Leukemia · 2022	Their institution	$65,990
JAZZ PHARMACEUTICALS INC. · V-Fast: A Phase 1b Master Trial To Investigate Cpx-351 Combined With Various Targeted Agents in Subjects With Previously Untreated Acute Myeloid Leukemia · 2024	Their institution	$63,322
Celgene Corporation · Ph Ib Monotherapy R/R Aml & R/R Mds - A Phase 1, Open-Label, Dose Finding Study of Cc-95251 Alone and in Combination With Antineoplastic Agents in Subjects With Acute Myeloid Leukemia and Myelodysplastic Syndromes · 2024	Their institution	$59,127
Pharmacyclics LLC, an AbbVie Company · An Open-Label Extension Study in Patients 65 Years Or Older With Chronic Lymphocytic Leukemia (Cll) Or Small Lymphocytic Lymphoma (Sll) Who Participated in Study Pcyc-1115-CA (Pci-32765 Versus Chlorambucil) · 2023	Their institution	$53,077
Siemens Medical Solutions USA, Inc. · The Feasibility of Telehealth-Based Palliative Care Intervention and Digital Symptom Monitoring on Patients Diagnosed With Aml · 2022	Their institution	$50,000
Stemline Therapeutics Inc. · Stml-401-0423 - A Phase II Multicenter Open -Label Trial of Tagraxofusp (Tag) in Combination With Venetoclax and Azacitidine (Ven/Aza) in Adults With Previously Untreated Cd123+ Acute Myeloid Leukemia (Aml) Who Are Ineligible for Intensive Chemotherapy · 2025	Their institution	$40,499
Siemens Medical Solutions USA, Inc. · The Feasibility of Telehealth-Based Palliative Care Intervention and Digital Symptom Monitoring on Patients Diagnosed With Aml Receiving Low-Intensity · 2023	Their institution	$25,000
Janssen Research & Development, LLC · A Phase 3b Multi Center Open Label Pci32765 Ibrutinib Long Term Extension Study · 2023	Their institution	$24,047
TAIHO ONCOLOGY, INC. · Pharmacokinetics, Safety, and Efficacy of Astx727 in Combination With Venetoclax in Acute Myeloid Leukemia (Aml)Pharmacokinetics, Safety, and Efficacy of Astx727 in Combination With Venetoclax in Acute Myeloid Leukemia (Aml) · 2025	Their institution	$21,632
ImmunoGen, Inc. · A Phase 1/2, Multi-Center, Open-Label Study of Imgn632 Monotherapy Administered Intravenously in Patients With Cd123-Positive Acute Myeloid Leukemia and Other Cd123-Positive Hematologic Malignancies · 2023	Their institution	$20,705
Pharmacyclics LLC, an AbbVie Company · An Open-Label Extension Study in Patients 65 Years Or Older With Chronic Lymphocytic Leukemia (Cll) Or Small Lymphocytic Lymphoma (Sll) Who Participated in Study Pcyc-1115-CA (Pci-32765 Versus Chlorambucil) · 2022	Their institution	$20,003
Genentech, Inc. · Ph Ib Combination Study in Mds With Azacitidine Apdl1 · 2019	Their institution	$17,383
Janssen Research & Development, LLC · A Phase 3b Multi Center Open Label Pci32765 Ibrutinib Long Term Extension Study · 2022	Their institution	$14,754
Siemens Medical Solutions USA, Inc. · 2025	Their institution	$14,716
Siemens Medical Solutions USA, Inc. · 2023	Their institution	$14,716
Siemens Medical Solutions USA, Inc. · 2024	Their institution	$14,716
MACROGENICS, INC. · Flotetuzumab in Primary Induction Failure Pif Or Early Relapse Er Acute Myeloid Leukemia Aml · 2021	Their institution	$13,175
Siemens Medical Solutions USA, Inc. · The Feasibility of Telehealth=Based Palliative Care Intervention and Digital Symptom Monitoring on Patients Diagnosed With Aml Receiving Low Intensity · 2022	Their institution	$12,821
JAZZ PHARMACEUTICALS INC. · V-Fast: A Phase 1b Master Trial To Investigate Cpx-351 Combined With Various Targeted Agents in Subjects With Previously Untreated Acute Myeloid Leukemia · 2023	Their institution	$9,109
TAIHO ONCOLOGY, INC. · Pharmacokinetics, Safety, and Efficacy of Astx727 in Combination With Venetoclax in Acute Myeloid Leukemia (Aml) · 2025	Their institution	$7,521
ImmunoGen, Inc. · A Phase 1/2, Multi-Center, Open-Label Study of Imgn632 Monotherapy Administered Intravenously in Patients With Cd123-Positive Acute Myeloid Leukemia and Other Cd123-Positive Hematologic Malignancies · 2024	Their institution	$6,208
ABBVIE INC. · A Phase 1/2, Multi-Center, Open-Label Study of Imgn632 Monotherapy Administered Intravenously in Patients With Cd123-Positive Acute Myeloid Leukemia and Other Cd123-Positive Hematologic Malignancies · 2024	Their institution	$3,200
Janssen Research & Development, LLC · A Phase 3b Multi Center Open Label Pci32765 Ibrutinib Long Term Extension Study · 2024	Their institution	$1,838
Sumitomo Pharma America, Inc. · A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of Dsp 5336 in Adult Patients With Acute Leukemia and Other Selected Hematologic Malignancies, With and Without Mixed Lineage Leukemia (Mll) Rearrangement Or Nucleophosmin 1 (Npm1) Mutation · 2025	Their institution	$1,717
Boehringer Ingelheim International GmbH · Baml-16-001-S2/Bi 836858 With 5-Aza · 2019	Their institution	$724

Checkups this office reported

Medicare did not publish checkup rates for this clinician.

Medicare’s overall office score: 76.5 / 100; Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.

Professional record

NPI: 1881929347
Licence: CA A110736California A110736: Current · expires 2028-01-31
Trained: University of California, Davis School of Medicine, 2008
Group: Stanford Health Care
Video visits: Lists video visits
Gender: Male

More record details

Sole proprietor: No
Taxonomy: Medical oncology (207RX0202X); Internal medicine (207R00000X); Federal specialty code 207RH0000X (207RH0000X); Federal specialty code 207RH0003X (207RH0003X)
Mailing address: 300 Pasteur Dr, Stanford, CA, 94305
NPI first listed: 2009-10-16
NPI last updated: 2024-04-12
NPI record certified: 2024-04-12

This is when the NPI record was last certified, not a medical board exam.

Extra NPI addresses: UCSF, San Francisco, CA, 94143